 Recently, a phase I dose-escalation study of NGR-hTNF has explored the dose range between 0.2 and 60 μgm2, showing DLT at 60 mcgm2 experienced as transient acute infusion reaction few minutes after the first administration start. Considering the relationship with the infusion of these events, a further dose escalation will be explored in the present phase I study by using both a longer infusion time i.e., 120 minutes instead of 60 minutes and a mild premedication. 